The rise of Viagra and its impact on the medicinal landscape presents a intricate question for shareholders. While the initial sales statistics were astounding, the intellectual property has expired, leading to a deluge of copycat alternatives that are reducing profit. Moreover, the industry is facing difficulties related to demographic trends a… Read More